Related Experiment Video
Updated: Jan 24, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Liver disease secondary to congenital heart disease in children
Haruki Komatsu1, Ayano Inui2, Kanako Kishiki3
1a Department of Pediatrics , Toho University, Sakura Medical Center , Chiba , Japan.
Insights
Children with congenital heart disease may develop hepatic fibrosis and liver cancer. Regular cardiac hepatopathy screening is crucial for those with single ventricle physiology and heart failure, regardless of Fontan operation status.
Area of Science:
- Pediatric Cardiology
- Hepatology
- Congenital Heart Disease
Background:
- Congenital heart disease (CHD) can lead to cardiac hepatopathy, characterized by hepatic fibrosis and hepatocellular carcinoma (HCC).
- These liver conditions can occur with or without the Fontan operation, highlighting the systemic impact of CHD.
Purpose of the Study:
- To review the history and mechanisms of cardiac hepatopathy in children with CHD.
- To propose a follow-up management flowchart for cardiac hepatopathy.
- To emphasize the need for regular screening in at-risk pediatric populations.
Main Methods:
- Review of patient characteristics, liver histology, imaging, and blood tests.
- Historical analysis of cardiac hepatopathy and Fontan-associated liver disease.
- Development of a proposed management flowchart.
Main Results:
- Congestion and low cardiac output are identified as primary causes of cardiac hepatopathy.
- Advanced hepatic fibrosis is linked to HCC development in adolescents and young adults.
- Current laboratory parameters and elastography show inconsistent results for cardiac hepatopathy detection.
Conclusions:
- Children with functional single ventricle and chronic heart failure require regular cardiac hepatopathy surveillance.
- Standardized evaluation protocols and liver specimen-confirmed studies are needed to understand cardiac hepatopathy pathogenesis.
- Early detection and management are critical for improving outcomes in pediatric CHD patients.
Abstract:
Introduction: Hepatic fibrosis and hepatocellular carcinoma (HCC) can develop in children with congenital heart disease. Although hepatic fibrosis and HCC are prone to develop after the Fontan operation, they can also develop in patients suffering from congenital heart disease who have not undergone Fontan operation. Area covered: The history of cardiac hepatopathy including Fontan-associated liver disease is described. Patient characteristics, liver histology, imaging examinations and blood tests are reviewed to elucidate the mechanism of cardiac hepatopathy. In addition, a flowchart for the follow-up management of cardiac hepatopathy in children with congenital heart disease is proposed. Expert opinion: Congestion and low cardiac output are the main causes of cardiac hepatopathy. Advanced hepatic fibrosis is presumed to be associated with HCC. HCC can develop in both adolescents and young adults. Regardless of whether the Fontan operation is performed, children with a functional single ventricle and chronic heart failure should be regularly examined for cardiac hepatopathy. There is no single reliable laboratory parameter to accurately detect cardiac hepatopathy; hepatic fibrosis indices and elastography have shown inconsistent results for detection of this disease. Further studies using liver specimen-confirmed patients and standardization of evaluation protocols are required to clarify the pathogenesis of cardiac hepatopathy.
More Related Videos
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

